As such, most of these generally younger patients with targetable mutations, except for those with MET exon 14 skipping mutations, have several YLL as they do not reach the general population's median life expectancy even if they were to receive all known approved targeted therapies for the mutation in their NSCLC. Here, MET is linked to non-small cell lung carcinoma.